The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...

Researchers have discovered factors that may make breast and ovarian cancers associated with BRCA1/2 gene mutations more likely to recur. Researchers at the University of Pennsylvania's Basser Center ...

Patients with BRCA-mutant breast cancer had a significantly higher risk of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL), a large cohort study showed. BRCA1/2 mutations conferred ...

More and more studies show that men face risks of cancer from BRCA1 and BRCA2 genetic mutations that are most often associated with breast and ovarian cancers in women. According to a July 25 JAMA ...

A new statement by the American College of Medical Genetics and Genomics (ACMG), published in the journal Genetics in Medicine, discusses the place of germline genetic testing in breast cancer ...

Is the mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin (ddTC) than to conventional taxane and carboplatin chemotherapy (TC) in high grade ...

Metastatic breast cancer has a poor prognosis, but emerging targeted therapies are providing some progress in the treatment of the disease, explained Filipa Lynce, MD, medical oncologist at ...

Researchers have uncovered how tumor cells interact with the immune system in ovarian cancer. Utilizing highly multiplex immunofluorescence and image analysis, they investigated how the genetic ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...